The estimated Net Worth of Isabelle Billet is at least $349 Thousand dollars as of 27 December 2022. Ms. Billet owns over 1,150 units of Axogen stock worth over $337,206 and over the last 6 years she sold AXGN stock worth over $11,559. In addition, she makes $0 as Chief Strategy and Business Development Officer at Axogen.
Sign up
Ms. Billet AXGN stock SEC Form 4 insiders trading
Isabelle has made over 5 trades of the Axogen stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 1,150 units of AXGN stock worth $15,272 on 27 December 2022.
The largest trade she's ever made was exercising 8,500 units of Axogen stock on 16 March 2022 worth over $112,880. On average, Isabelle trades about 1,220 units every 88 days since 2018. As of 27 December 2022 she still owns at least 25,392 units of Axogen stock.
You can see the complete history of Ms. Billet stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Isabelle Billet biography
Isabelle Billet serves as Chief Strategy and Business Development Officer of the Company. Ms. Billet has served as Axogen’s Chief Strategy and Business Development Officer since October 2018. From July 2013 until joining Axogen as Chief Strategy and Business Development Officer, Ms. Billet worked for IBHC Advisors LLC, a consulting firm she founded which assisted medical device companies in their organic and inorganic growth strategies and supported private equity firms on their investment strategy and due diligence. From 2010 to 2013, Ms. Billet worked at Cardinal Health, Inc where she served as Senior Vice President of Marketing and Innovation for the Medical segment focusing on their private brand portfolio development. From 2005 to 2010, she was Vice President Marketing and New Business Development for C.R. Bard Medical division. She worked for Johnson and Johnson from 1992 to 2005, splitting her tenure between Advanced Sterilization Products and Ethicon, Inc in positions of increasing responsibilities in marketing and new business development in France, Europe and US. Ms. Billet spent the first 7 years of her career as the head pharmacist and material manager for a private hospital in France. Ms. Billet is a member of the Clinical Innovations Board of Directors, a medical device company exclusively focused in Labor and Delivery and Neonates Intensive Care. She has an MBA from EM Lyon Business School, France and Cranfield School of Management, UK and a Doctorate in Pharmacy from Montpellier University in France.
How old is Isabelle Billet?
Isabelle Billet is 58, she's been the Chief Strategy and Business Development Officer of Axogen since 2018. There are 7 older and 7 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
What's Isabelle Billet's mailing address?
Isabelle's mailing address filed with the SEC is 13631 Progress Blvd #400, Alachua, FL 32615, USA.
Insiders trading at Axogen
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels, and Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
What does Axogen do?
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
What does Axogen's logo look like?
Complete history of Ms. Billet stock trades at Axogen
Axogen executives and stock owners
Axogen executives and other stock owners filed with the SEC include:
-
Eric Sandberg,
Chief Commercial Officer -
Karen Zaderej,
Chairman of the Board, President, Chief Executive Officer -
Gregory Freitag,
Director -
Angelo Scopelianos,
Vice President - Research and Development -
Peter Mariani,
Chief Financial Officer -
Maria Martinez,
Chief Human Resource Officer -
Quentin Blackford,
Independent Director -
Alan Levine,
Independent Director -
Amy Wendell,
Lead Independent Director -
Mark Gold,
Independent Director -
Guido Neels,
Independent Director -
Paul Thomas,
Director -
Brad Ottinger,
Chief Compliance Officer, General Counsel -
Isabelle Billet,
Chief Strategy and Business Development Officer -
Mark Friedman,
Vice President - Regulatory Affairs and Quality Assurance -
Erick DeVinney,
Vice President - Clinical and Translational Sciences -
Mike Donovan,
Vice President - Operations -
James E Deerfield Mgmt L.P....,
-
John P Engels,
Vice President -
Jamie Mark Grooms,
Director -
Robert James Rudelius,
Director -
Joseph M Mandato,
Director -
Shawn F Mccarrey,
SVP of Sales -
Lisa N Colleran,
Director -
Jon S. Gingrich,
Chief Commercial Officer -
Woodlands Fund Ix, L.P. Essex,
10% owner -
Kevin Leach,
Vice President Marketing -
Kathy Johnson Weiler,
Director -
William P. Mr. Burke,
Director -
Lee Robert Jr Johnston,
Chief Financial Officer -
Jill F Schiaparelli,
SVP, Bus. Strategy&Marketing -
John Frederick Harper,
Director -
Bradley Jay Hedger,
Vice President, Sales -
David K Hansen,
VP Finance & Treasurer -
Michael Patrick Donovan,
VP Operations -
Joseph A. Tyndall,
Director -
John Johnson,
Director -
Nir Naor,
CFO -
Marc A Began,
EVP and General Counsel -
Jens Kemp,
Chief Marketing Officer -
Michael D Dale,
CEO and President